Default company panoramic image
Db4c06b8 fdc4 4a4b 8a6e bc2353208fe3

CardioCeption, LLC

CardioCeption has developed a skin patch device to treat various ischemic indications using remote conditioning via nerve receptors.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Cincinnati, OH, USA
  • Currency USD
  • Founded September 2009
  • Employees 0

Company Summary

CardioCeption is focused on development and sale of proprietary devices to treat cardiovascular ischemic disease. The electrical patch device will be applied immediately after STEMI confirmation (ambulance/ED), adjunct to reperfusion (PCI or CABG). Our approach offers a simple, inexpensive (~$200/patch) approach (electrical stimulation), which has been safely used in other indications aiding acceptance with EMT's, ER M.D.'s, and surgeons.


  • Default avatar
    Clint G. Dederick, Jr
    Managing Member, CEO

    Over 30 years experience with Eli Lilly, a venture capital firm, and as a transitional CEO of multiple university spin out companies.

  • Default avatar
    W. Keith Jones, Ph.D.
    President, V.P. R&D

    A faculty member at the University of Louisville and the University of Cincinnati, where I am today. My research program has been funded by AHA and NIH continuously since 1996. I have served on numerous NIH, AHA, VA, and other study sections Nationally and Internationally and am recognized for my detailed and rigorous science. Neal and I founded CardioCeption to commercialize novel cardioprotection initiated by skin sensory nerve stimulation.

  • Default avatar
    Neal Weintraub, M.D.
    V.P. Clinical Affairs

    Neal has just become the Herbert S. Kupperman, M.D., Eminent Scholar in Cardiovascular Medicine
    Professor of Medicine, Section of Cardiology at Georgia Regents University. He along with Keith are the scientific founders of the company. He has been continually funded as a principal investigator by the NIH since 1997. I am a recognized expert in the field of atherosclerosis and currently serve as Chair of the NIH study section on athersclerosis a


  • Default avatar
    David Willbrand, Thompson Hine, Cincinnati, OH
    Default avatar
    Laura DeSalvo, DeSalvo CPA, Cincinnati, OH